Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 9, 2015, Pages 1676-1682.e1

  Hayashi, Paul H ^a   Fontana, Robert J ^b   Chalasani, Naga P ^c   Stolz, Andrew A ^d   Talwalkar, Jay A ^e   Navarro, Victor J ^f   Lee, William M ^g   Davern, Timothy J ^h   Kleiner, David E ⁱ   Gu, Jiezhun ^j   Hoofnagle, Jay H ^k  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^k NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

Adverse Reaction; Antibiotics; Drug Induced Liver Injury; Hepatotoxicity; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH PROGRAM; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; ADOLESCENT; AGED; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH SERVICES RESEARCH; PATHOLOGY; PRESCHOOL CHILD; PROTOCOL COMPLIANCE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTITUBERCULAR AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84939563615     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.02.024     Document Type: Article

References (25)

1. Garibaldi R.A., Drusin R.E., Ferebee S.H., et al. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972, 106:357-365.
2. Runyon E.H. Preventive treatment in tuberculosis: a statement by the Committee on Therapy, American Thoracic Society. Am Rev Respir Dis 1965, 91:297-298.
3. Randolph H., Joseph S. Toxic hepatitis with jaundice occurring in a patient treated with isoniazid. J Am Med Assoc 1953, 152:38-40.
4. Gellis S.N., Murphy R.V. Hepatitis following isoniazid. Dis Chest 1955, 28:462-464.
5. LiverTox: isoniazid. Available: . Accessed: June 6, 2013. http://livertox.nlm.nih.gov/isoniazid.htm.
6. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
7. Nolan C.M., Goldberg S.V., Buskin S.E. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999, 281:1014-1018.
8. LoBue P.A., Moser K.S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003, 168:443-447.
9. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010, 59:224-229.
10. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009, 32:55-68.
11. Sterling T.R., Bethel J., Goldberg S., et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006, 173:927-931.
12. Centers for Disease Control. Tuberculosis. Available: . Accessed: July 27, 2013. http://www.cdc.gov/tb/statistics/default.htm.
13. Severe isoniazid-associated hepatitis-New York, 1991-1993. MMWR Morb Mortal Wkly Rep 1993, 42:545-547.
14. Gayle H.D., Castro K.G. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000, 49:1-54.
15. Nolan C.M. Isoniazid for latent tuberculosis infection: approaching 40 and reaching its prime. Am J Respir Crit Care Med 2003, 168:412-413.
16. American Lung Association. Trends in tuberculosis morbidity and mortality. Available: . Accessed: November 12, 2013. http://www.lung.org/finding-cures/our-research/trend-reports/TB-Trend-Report.pdf.
17. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009, 15:719-729.
18. Bjornsson E.S., Bergmann O.M., Bjornsson H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144:1419-1425 e1413.
19. Pollock N.R., Rolland J.P., Kumar S., et al. A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med 2012, 4:152ra129.
20. Smith A. Smartphone ownership 2013. Pew Research Internet Project. Available: . Accessed: October 15, 2014. http://www.pewinternet.org/2013/06/05/smartphone-ownership-2013/.
21. Nglazi M.D., Bekker L.G., Wood R., et al. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis 2013, 13:566.
22. Danielides I.C., Constantoulakis M., Daikos G.K. Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis. Am J Gastroenterol 1983, 78:378-380.
23. Sharma S.K., Singla R., Sarda P., et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50:833-839.
24. Mitchell J.R., Long M.W., Thorgeirsson U.P., et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975, 68:181-190.
25. Mitchell J.R., Zimmerman H.J., Ishak K.G., et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976, 84:181-192.